Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 48 studies | 77% ± 17% | |
CD8-positive, alpha-beta T cell | 29 studies | 37% ± 15% | |
mature NK T cell | 21 studies | 64% ± 19% | |
gamma-delta T cell | 19 studies | 61% ± 12% | |
CD16-negative, CD56-bright natural killer cell, human | 18 studies | 79% ± 14% | |
T cell | 17 studies | 29% ± 11% | |
CD16-positive, CD56-dim natural killer cell, human | 17 studies | 83% ± 11% | |
effector memory CD8-positive, alpha-beta T cell | 11 studies | 45% ± 11% | |
mucosal invariant T cell | 10 studies | 23% ± 7% | |
CD8-positive, alpha-beta memory T cell | 9 studies | 41% ± 11% | |
innate lymphoid cell | 7 studies | 47% ± 31% | |
effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 6 studies | 45% ± 14% | |
effector CD8-positive, alpha-beta T cell | 6 studies | 47% ± 18% | |
lymphocyte | 5 studies | 32% ± 12% | |
central memory CD8-positive, alpha-beta T cell | 4 studies | 20% ± 1% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 37% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 94% | 268.48 | 337 / 359 | 37% | 0.92 | 106 / 286 |
lung | 100% | 1186.79 | 578 / 578 | 31% | 0.67 | 355 / 1155 |
kidney | 79% | 149.58 | 70 / 89 | 42% | 0.80 | 380 / 901 |
uterus | 94% | 176.69 | 160 / 170 | 19% | 0.49 | 88 / 459 |
breast | 93% | 267.37 | 425 / 459 | 20% | 0.39 | 221 / 1118 |
esophagus | 81% | 130.14 | 1170 / 1445 | 29% | 0.61 | 53 / 183 |
thymus | 94% | 227.57 | 614 / 653 | 10% | 0.17 | 59 / 605 |
liver | 98% | 272.92 | 221 / 226 | 6% | 0.10 | 23 / 406 |
intestine | 83% | 276.96 | 799 / 966 | 20% | 0.41 | 104 / 527 |
spleen | 100% | 3878.88 | 241 / 241 | 0% | 0 | 0 / 0 |
bladder | 81% | 227.90 | 17 / 21 | 18% | 0.40 | 89 / 504 |
adipose | 98% | 343.94 | 1180 / 1204 | 0% | 0 | 0 / 0 |
prostate | 93% | 207.29 | 228 / 245 | 3% | 0.04 | 14 / 502 |
heart | 83% | 176.29 | 715 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 83% | 2783.52 | 768 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 77% | 145.99 | 1031 / 1335 | 0% | 0 | 0 / 0 |
ovary | 51% | 88.26 | 91 / 180 | 6% | 0.10 | 27 / 430 |
brain | 52% | 61.40 | 1386 / 2642 | 1% | 0.02 | 9 / 705 |
adrenal gland | 52% | 60.40 | 133 / 258 | 2% | 0.04 | 4 / 230 |
pancreas | 32% | 38.98 | 106 / 328 | 16% | 0.24 | 29 / 178 |
skin | 20% | 22.74 | 362 / 1809 | 25% | 0.69 | 120 / 472 |
lymph node | 0% | 0 | 0 / 0 | 41% | 1.18 | 12 / 29 |
tonsil | 0% | 0 | 0 / 0 | 38% | 0.77 | 17 / 45 |
muscle | 24% | 28.50 | 189 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 3% | 0.03 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0045953 | Biological process | negative regulation of natural killer cell mediated cytotoxicity |
GO_0002228 | Biological process | natural killer cell mediated immunity |
GO_0001915 | Biological process | negative regulation of T cell mediated cytotoxicity |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0032814 | Biological process | regulation of natural killer cell activation |
GO_0002223 | Biological process | stimulatory C-type lectin receptor signaling pathway |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0023030 | Molecular function | MHC class Ib protein binding, via antigen binding groove |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_1990405 | Molecular function | protein antigen binding |
GO_0062082 | Molecular function | HLA-E specific inhibitory MHC class Ib receptor activity |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
GO_0023024 | Molecular function | MHC class I protein complex binding |
Gene name | KLRD1 |
Protein name | Natural killer cells antigen CD94 (KP43) (Killer cell lectin-like receptor subfamily D member 1) (NK cell receptor) (CD antigen CD94) Killer cell lectin like receptor D1 Killer cell lectin-like receptor subfamily D transcript B2 Killer cell lectin-like receptor subfamily D transcript 3 Natural killer cells antigen CD94 (Killer cell lectin-like receptor subfamily D member 1) |
Synonyms | CD94 hCG_37262 |
Description | FUNCTION: Immune receptor involved in self-nonself discrimination. In complex with KLRC1 or KLRC2 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia and non-classical MHC class Ib molecules . Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self . Primarily functions as a ligand binding subunit as it lacks the capacity to signal. .; FUNCTION: KLRD1-KLRC1 acts as an immune inhibitory receptor. Key inhibitory receptor on natural killer (NK) cells that regulates their activation and effector functions . Dominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity . On intraepithelial CD8-positive gamma-delta regulatory T cells triggers TGFB1 secretion, which in turn limits the cytotoxic programming of intraepithelial CD8-positive alpha-beta T cells, distinguishing harmless from pathogenic antigens . In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell exhaustion . Upon HLA-E-peptide binding, transmits intracellular signals through KLRC1 immunoreceptor tyrosine-based inhibition motifs (ITIMs) by recruiting INPP5D/SHIP-1 and INPPL1/SHIP-2 tyrosine phosphatases to ITIMs, and ultimately opposing signals transmitted by activating receptors through dephosphorylation of proximal signaling molecules . .; FUNCTION: KLRD1-KLRC2 acts as an immune activating receptor . On cytotoxic lymphocyte subsets recognizes HLA-E loaded with signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules, likely playing a role in the generation and effector functions of adaptive NK cells and in maternal-fetal tolerance during pregnancy . Regulates the effector functions of terminally differentiated cytotoxic lymphocyte subsets, and in particular may play a role in adaptive NK cell response to viral infection . Upon HLA-E-peptide binding, transmits intracellular signals via the adapter protein TYROBP/DAP12, triggering the phosphorylation of proximal signaling molecules and cell activation . .; FUNCTION: (Microbial infection) Viruses like human cytomegalovirus have evolved an escape mechanism whereby virus-induced down-regulation of host MHC class I molecules is coupled to the binding of viral peptides to HLA-E, restoring HLA-E expression and inducing HLA-E-dependent NK cell immune tolerance to infected cells. Recognizes HLA-E in complex with human cytomegalovirus UL40-derived peptide (VMAPRTLIL) and inhibits NK cell cytotoxicity. .; FUNCTION: (Microbial infection) May recognize HLA-E in complex with HIV-1 gag/Capsid protein p24-derived peptide (AISPRTLNA) on infected cells and may inhibit NK cell cytotoxicity, a mechanism that allows HIV-1 to escape immune recognition. .; FUNCTION: (Microbial infection) Upon SARS-CoV-2 infection, may contribute to functional exhaustion of cytotoxic NK cells and CD8-positive T cells . On NK cells, may recognize HLA-E in complex with SARS-CoV-2 S/Spike protein S1-derived peptide (LQPRTFLL) expressed on the surface of lung epithelial cells, inducing NK cell exhaustion and dampening antiviral immune surveillance . . |
Accessions | ENST00000344825.10 H0YFB8 Q53ZY6 ENST00000336164.9 [Q13241-1] F5GX94 ENST00000543777.5 ENST00000539792.1 ENST00000543420.5 E9PCX9 F5H2B7 Q8NFL9 ENST00000381908.7 [Q13241-1] ENST00000544747.5 Q8NFM0 ENST00000539374.1 F6WZH4 ENST00000350274.9 [Q13241-3] Q13241 |